Loustau T, Mitrentsi I, Wang N, Spenlé C, Pavlidaki A, Tranchant T, Riegel G, Venu A, Oueidat R, Koch M, Dumas M, Wack F, Hirschler A, Carapito C, Paul N, Carapito R, Mörgelin M, Hansen U, Azzi J, Aubergeon L, Salomé N, Dhaouadi S, Grenot P, Bouhaouala-Zahar B, La Cioppa S, Oertle P, Izzi V, Plodinec M, Noel G, Burckel H, Orend G

EMBO Mol Med. 2026 03 31;:

Targeting the extracellular matrix with Tenascin-C-specific CAR T cells extends survival in preclinical models of glioblastoma.

de Sostoa J, Marinari E, Pedard M, Widmer V, Davanture S, Schaller K, Tissot S, De Palma M, Wolf B, Orend G, Dutoit V, Migliorini D

J Immunother Cancer. 2025 11 4;13(11):

Granzyme B cleaves Tenascin-C to release its C-terminal domain in rheumatoid arthritis.

Aubert A, Liu A, Kao M, Goeres J, Richardson KC, Nierves L, Jung K, Nabai L, Zhao H, Orend G, Krawetz R, Lange PF, Younger A, Chan J, Granville DJ

JCI Insight. 2024 10 17;:

Targeting the MAtrix REgulating MOtif abolishes several hallmarks of cancer, triggering antitumor immunity.

Li C, Kaur A, Pavlidaki A, Spenlé C, Rajnpreht I, Donnadieu E, Salomé N, Molitor A, Carapito R, Wack F, Erne W, Lefebvre O, Averous G, Mitrentsi I, Loustau T, Orend G

Proc Natl Acad Sci U S A. 2024 10 15;121(42):e2404485121

Tenascin-C targeting strategies in cancer.

Dhaouadi S, Bouhaouala-Zahar B, Orend G

Matrix Biol. 2024 04 18;:

Investigating Chemokine-Matrix Networks in Breast Cancer: Tenascin-C Sets the Tone for CCL2.

Gschwandtner M, Gammage AN, Deligne C, Mies LFM, Domaingo A, Murdamoothoo D, Loustau T, Schwenzer A, Derler R, Carapito R, Koch M, Mörgelin M, Orend G, Kungl AJ, Midwood KS

Int J Mol Sci. 2023 05 6;24(9):

How the mechanobiology orchestrates the iterative and reciprocal ECM-cell cross-talk that drives microtissue growth.

Benn MC, Pot SA, Moeller J, Yamashita T, Fonta CM, Orend G, Kollmannsberger P, Vogel V

Sci Adv. 2023 03 29;9(13):eadd9275

Infiltrating CD8+ T cells and M2 macrophages are retained in tumor matrix tracks enriched in low tension fibronectin fibers.

Fonta CM, Loustau T, Li C, Surendran SP, Hansen U, Murdamoothoo D, Benn MC, Velazquez-Quesada I, Carapito R, Orend G, Vogel V

Matrix Biol. 2023 01 17;:

Dicer1 deficient mice exhibit premature aging and metabolic perturbations in adipocytes.

De Cauwer A, Loustau T, Erne W, Pichot A, Molitor A, Stemmelen T, Carapito R, Orend G, Bahram S, Georgel P

iScience. 2022 10 21;25(10):105149

Advances on the roles of tenascin-C in cancer.

Yilmaz A, Loustau T, Salomé N, Poilil Surendran S, Li C, Tucker RP, Izzi V, Lamba R, Koch M, Orend G

J Cell Sci. 2022 09 15;135(18):

Modulating tenascin-C functions by targeting the MAtrix REgulating MOtif, "MAREMO".

Loustau T, Abou-Faycal C, Erne W, Zur Wiesch PA, Ksouri A, Imhof T, Mörgelin M, Li C, Mathieu M, Salomé N, Crémel G, Dhaouadi S, Bouhaouala-Zahar B, Koch M, Orend G

Matrix Biol. 2022 Feb 25;:

An adapted passive model of anti-MPO dependent crescentic glomerulonephritis reveals matrix dysregulation and is amenable to modulation by CXCR4 inhibition.

Faycal CA, Oszwald A, Feilen T, Contreras MJC, Schilling O, Loustau T, Steinbach F, Schachner H, Langer B, Heeringa P, Rees AJ, Orend G, Kain R

Matrix Biol. 2022 Jan 12;:

Tenascin C Has a Modest Protective Effect on Acute Lung Pathology during Methicillin-Resistant Staphylococcus aureus-Induced Pneumonia in Mice.

Meijer MT, de Vos AF, Peters Sengers H, Scicluna BP, Roelofs JJ, Abou Fayçal C, Uhel F, Orend G, van der Poll T

Microbiol Spectr. 2021 Jul 28;:e0020721

Tenascin-C immobilizes infiltrating T lymphocytes through CXCL12 promoting breast cancer progression.

Murdamoothoo D, Sun Z, Yilmaz A, Riegel G, Abou-Faycal C, Deligne C, Velazquez-Quesada I, Erne W, Nascimento M, Mörgelin M, Cremel G, Paul N, Carapito R, Veber R, Dumortier H, Yuan J, Midwood KS, Loustau T, Orend G

EMBO Mol Med. 2021 May 14;:e13270

Did Tenascin-C Co-Evolve With the General Immune System of Vertebrates?

Orend G, Tucker RP

Front Immunol. 2021 ;12:663902

Editorial: Tenascins - Key Players in Tissue Homeostasis and Defense.

Yoshida KI, Midwood KS, Orend G

Front Immunol. 2021 ;12:834353

Impact of Tenascin-C on Radiotherapy in a Novel Syngeneic Oral Squamous Cell Carcinoma Model With Spontaneous Dissemination to the Lymph Nodes.

Spenlé C, Loustau T, Burckel H, Riegel G, Abou Faycal C, Li C, Yilmaz A, Petti L, Steinbach F, Ahowesso C, Jost C, Paul N, Carapito R, Noël G, Anjuère F, Salomé N, Orend G

Front Immunol. 2021 ;12:636108

Novel Human Tenascin-C Function-Blocking Camel Single Domain Nanobodies.

Dhaouadi S, Ben Abderrazek R, Loustau T, Abou-Faycal C, Ksouri A, Erne W, Murdamoothoo D, Mörgelin M, Kungl A, Jung A, Ledrappier S, Benlasfar Z, Bichet S, Chiquet-Ehrismann R, Hendaoui I, Orend G, Bouhaouala-Zahar B

Front Immunol. 2021 ;12:635166

Tenascin-C Deficiency Is Associated With Reduced Bacterial Outgrowth During -Evoked Pneumosepsis in Mice.

Meijer MT, de Vos AF, Scicluna BP, Roelofs JJ, Abou Fayçal C, Orend G, Uhel F, van der Poll T

Front Immunol. 2021 ;12:600979

ECM deposition is driven by caveolin-1-dependent regulation of exosomal biogenesis and cargo sorting.

Albacete-Albacete L, Navarro-Lérida I, López JA, Martín-Padura I, Astudillo AM, Ferrarini A, Van-Der-Heyden M, Balsinde J, Orend G, Vázquez J, Del Pozo MÁ

J Cell Biol. 2020 Nov 2;219(11):

Tenascin-C orchestrates an immune suppressive tumor microenvironment in oral squamous cell carcinoma.

Spenlé C, Loustau T, Murdamoothoo D, Erne W, Beghelli-de la Forest Divonne S, Veber R, Petti L, Bourdely P, Mörgelin M, Brauchle EM, Crémel G, Randrianarisoa V, Camara A, Rekima S, Schaub S, Nouhen K, Imhof T, Hansen U, Paul N, Carapito R, Pythoud N, Hirschler A, Carapito C, Dumortier H, Mueller CG, Koch M, Schenke-Layland K, Kon S, Sudaka A, Anjuere F, Van Obberghen-Schilling E, Orend G

Cancer Immunol Res. 2020 Jul 14;:

Generation and characterization of dromedary Tenascin-C and Tenascin-W specific antibodies.

Dhaouadi S, Murdamoothoo D, Tounsi A, Erne W, Benabderrazek R, Benlasfar Z, Hendaoui L, Chiquet-Ehrismann R, Boubaker S, Orend G, Hendaoui I, Bouhaouala-Zahar B

Biochem. Biophys. Res. Commun.. 2020 Jun 24;:

Matrix-targeting immunotherapy controls tumor growth and spread by switching macrophage phenotype.

Deligne C, Murdamoothoo D, Gammage AN, Gschwandtner M, Erne W, Loustau T, Marzeda AM, Carapito R, Paul N, Velázquez-Quesada I, Mazzier I, Sun Z, Orend G, Midwood KS

Cancer Immunol Res. 2020 Jan 15;:

Functionalized Coat Protein Monomers and Oligomers as Nanocarriers for Anti-Cancer Peptides.

Gamper C, Spenlé C, Boscá S, van der Heyden M, Erhardt M, Orend G, Bagnard D, Heinlein M

Cancers (Basel). 2019 Oct 22;11(10):

Tenascin-C increases lung metastasis by impacting blood vessel invasions.

Sun Z, Velázquez-Quesada I, Murdamoothoo D, Ahowesso C, Yilmaz A, Spenlé C, Averous G, Erne W, Oberndorfer F, Oszwald A, Kain R, Bourdon C, Mangin P, Deligne C, Midwood K, Abou-Faycal C, Lefebvre O, Klein A, van der Heyden M, Chenard MP, Christofori G, Mathelin C, Loustau T, Hussenet T, Orend G

Matrix Biol.. 2019 Jul 6;:

Laminin α1 orchestrates VEGFA functions in the ecosystem of colorectal carcinoma.

Mammadova-Bach E, Rupp T, Spenlé C, Jivkov I, Shankaranarayanan P, Klein A, Pisarsky L, Méchine-Neuville A, Cremel G, Kedinger M, De Wever O, Ambartsumian N, Robine S, Pencreach E, Guenot D, Simon-Assmann P, Goetz JG, Orend G, Lefebvre O

Biol. Cell. 2018 Jun 15;:

Periostin Limits Tumor Response to VEGFA Inhibition.

Keklikoglou I, Kadioglu E, Bissinger S, Langlois B, Bellotti A, Orend G, Ries CH, De Palma M

Cell Rep. 2018 Mar 6;22(10):2530-2540

Tenascin-C Promotes Tumor Cell Migration and Metastasis through Integrin α9β1-Mediated YAP Inhibition.

Sun Z, Schwenzer A, Rupp T, Murdamoothoo D, Vegliante R, Lefebvre O, Klein A, Hussenet T, Orend G

Cancer Res.. 2018 Feb 15;78(4):950-961

How to detect and purify tenascin-C.

Giblin SP, Murdamoothoo D, Deligne C, Schwenzer A, Orend G, Midwood KS

Methods Cell Biol.. 2018 ;143:371-400

Investigating cell-type specific functions of tenascin-C.

Murdamoothoo D, Schwenzer A, Kant J, Rupp T, Marzeda A, Midwood K, Orend G

Methods Cell Biol.. 2018 ;143:401-428

Counterbalancing anti-adhesive effects of Tenascin-C through fibronectin expression in endothelial cells.

Radwanska A, Grall D, Schaub S, Divonne SBF, Ciais D, Rekima S, Rupp T, Sudaka A, Orend G, Obberghen-Schilling EV

Sci Rep. 2017 Oct;7(1):12762

Stem cells and matrix.

Oskarsson T, Orend G

Int. J. Biochem. Cell Biol.. 2016 Dec;81(Pt A):165

Tenascin-C at a glance.

Midwood KS, Chiquet M, Tucker RP, Orend G

J. Cell. Sci.. 2016 Dec;129(23):4321-4327

Tenascin-C Orchestrates Glioblastoma Angiogenesis by Modulation of Pro- and Anti-angiogenic Signaling.

Rupp T, Langlois B, Koczorowska MM, Radwanska A, Sun Z, Hussenet T, Lefebvre O, Murdamoothoo D, Arnold C, Klein A, Biniossek ML, Hyenne V, Naudin E, Velazquez-Quesada I, Schilling O, Van Obberghen-Schilling E, Orend G

Cell Rep. 2016 Dec;17(10):2607-2619

Inhibition of PlexA1-mediated brain tumor growth and tumor-associated angiogenesis using a transmembrane domain targeting peptide.

Jacob L, Sawma P, Garnier N, Meyer LA, Fritz J, Hussenet T, Spenlé C, Goetz J, Vermot J, Fernandez A, Baumlin N, Aci-Sèche S, Orend G, Roussel G, Crémel G, Genest M, Hubert P, Bagnard D

Oncotarget. 2016 09;7(36):57851-57865

Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell-derived ADAM9.

Mammadova-Bach E, Zigrino P, Brucker C, Bourdon C, Freund M, De Arcangelis A, Abrams SI, Orend G, Gachet C, Mangin PH

JCI Insight. 2016 Sep;1(14):e88245

Inhibition of primary breast tumor growth and metastasis using a neuropilin-1 transmembrane domain interfering peptide.

Arpel A, Gamper C, Spenlé C, Fernandez A, Jacob L, Baumlin N, Laquerriere P, Orend G, Crémel G, Bagnard D

Oncotarget. 2016 Aug;7(34):54723-54732

Autonomous Extracellular Matrix Remodeling Controls a Progressive Adaptation in Muscle Stem Cell Regenerative Capacity during Development.

Tierney MT, Gromova A, Sesillo FB, Sala D, Spenlé C, Orend G, Sacco A

Cell Rep. 2016 Mar;14(8):1940-52

A hypermorphic epithelial beta-catenin mutation facilitates intestinal tumorigenesis in mice in response to compounding WNT-pathway mutations.

Buchert M, Rohde F, Eissmann M, Tebbutt N, Williams B, Tan CW, Owen A, Hirokawa Y, Gnann A, Orend G, Orner G, Dashwood RH, Heath JK, Ernst M, Janssen KP

Dis Model Mech. 2015 Aug 6. pii: dmm.019844.

Spatial organization of the tenascin-C microenvironment in experimental and human cancer.

Spenle C, Gasser I, Saupe F, Janssen KP, Arnold C, Klein A, van der Heyden M, Mutterer J, Neuville-Mechine A, Chenard MP, Guenot D, Esposito I, Slotta-Huspenina J, Ambartsumian N, Simon-Assmann P, Orend G

Cell Adh Migr. 2015 Jan 22:0.

Special issue of Cell Adhesion & Migration on Tenascins: Defining their role in tissue homeostasis and cancer.

Midwood K, Orend G

Cell Adh Migr. 2015 Jan 2;9(1-2):1-3

Tenascin-C: exploitation and collateral damage in cancer management.

Spenle C, Saupe F, Midwood K, Burkel H, Noel G, Orend G

Cell Adh Migr. 2015 Jan 8:0.

Phosphonated chelates for nuclear imaging.

Abada S, Lecointre A, Christine C, Ehret-Sabatier L, Saupe F, Orend G, Brasse D, Ouadi A, Hussenet T, Laquerrière P, Elhabiri M, Charbonnière LJ

Org. Biomol. Chem.. 2014 Dec;12(47):9601-20

AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patients.

Langlois B, Saupe F, Rupp T, Arnold C, van der Heyden M, Orend G, Hussenet T

Oncotarget. 2014 Nov 15;5(21):10529-45.

Transmembrane domain targeting peptide antagonizing ErbB2/Neu inhibits breast tumor growth and metastasis.

Arpel A, Sawma P, Spenle C, Fritz J, Meyer L, Garnier N, Velazquez-Quesada I, Hussenet T, Aci-Seche S, Baumlin N, Genest M, Brasse D, Hubert P, Cremel G, Orend G, Laquerriere P, Bagnard D

Cell Rep. 2014 Sep 25;8(6):1714-21

Tenascins in stem cell niches.

Chiquet-Ehrismann R, Orend G, Chiquet M, Tucker RP, Midwood KS

Matrix Biol. 2014 Jul;37:112-23

Loss of SPARC protects hematopoietic stem cells from chemotherapy toxicity by accelerating their return to quiescence.

Ehninger A, Boch T, Medyouf H, Mudder K, Orend G, Trumpp A

Blood. 2014 Jun 26;123(26):4054-63

The laminin response in inflammatory bowel disease: protection or malignancy?

Spenle C, Lefebvre O, Lacroute J, Mechine-Neuville A, Barreau F, Blottiere HM, Duclos B, Arnold C, Hussenet T, Hemmerle J, Gullberg D, Kedinger M, Sorokin L, Orend G, Simon-Assmann P

PLoS One. 2014 Oct 27;9(10):e111336

Tenascin-C downregulates wnt inhibitor dickkopf-1, promoting tumorigenesis in a neuroendocrine tumor model.

Saupe F, Schwenzer A, Jia Y, Gasser I, Spenle C, Langlois B, Kammerer M, Lefebvre O, Hlushchuk R, Rupp T, Marko M, van der Heyden M, Cremel G, Arnold C, Klein A, Simon-Assmann P, Djonov V, Neuville-Mechine A, Esposito I, Slotta-Huspenina J, Janssen KP, de Wever O, Christofori G, Hussenet T, Orend G

Cell Rep. 2013 Oct 31;5(2):482-92

Laminin alpha5 guides tissue patterning and organogenesis.

Spenle C, Simon-Assmann P, Orend G, Miner JH

Cell Adh Migr. 2013 Jan-Feb;7(1):90-100

Synthesis of an activated phosphonated bifunctional chelate with potential for PET imaging and radiotherapy.

Christine C, Koubemba M, Shakir S, Clavier S, Ehret-Sabatier L, Saupe F, Orend G, Charbonniere LJ

Org Biomol Chem. 2012 Dec 14;10(46):9183-90

Dysregulation of laminins in intestinal inflammation.

Spenle C, Hussenet T, Lacroute J, Lefebvre O, Kedinger M, Orend G, Simon-Assmann P

Pathol Biol (Paris). 2012 Feb;60(1):41-7

Abnormal Wnt and PI3Kinase signaling in the malformed intestine of lama5 deficient mice.

Ritie L, Spenle C, Lacroute J, Bolcato-Bellemin AL, Lefebvre O, Bole-Feysot C, Jost B, Klein A, Arnold C, Kedinger M, Bagnard D, Orend G, Simon-Assmann P

PLoS One. 2012;7(5):e37710